PUBLICATION
Global Business Reports
Peru Mining 2014
October 16, 2014
The Peruvian government has outlined an ambitious $60 billion portfolio of mining projects, and the country’s geological richness and business-friendly environment will help it deliver, but it remains to be seen if it can continue to attract investment in the down market. Investment in the country’s mining industry was a record-breaking $9.5 billion in 2013, but Peru will need more projects after 2016 to keep up the pace. Several proposed projects are uncertain at the moment. GBR’s Spanish-language report examines the state of the Peruvian mining industry and offer fresh insights into the government and mining industry’s strategies for the medium- and long-term.
RELATED INTERVIEWS MORE INTERVIEWS
Tembo Power is developing hydropower projects across Africa with a focus on DRC.
Chesser Resources is upbeat about its Diamba Sud gold resource in Eastern Senegal.
Robocon speaks with GBR about the outlook for its services in Peru.
"Our product innovation process involves gathering client feedback and submitting it to the factory, which determines which ideas to pursue based on economic considerations."
RELATED ARTICLES MORE ARTICLES
B.C. Mining Enters an Era of Reconciliation
British Columbia Mining 2019 Pre-Release Edition
True cohesion between government, Indigenous groups and the sector is the priority.
The Global Tailings Standard
The mining industry and investment community are collaborating to mitigate a perpetual risk, after a series of high-profile disasters.
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED
MACIG
SUBSCRIBE TO OUR NEWSLETTER
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
